Beta-sitosterol Cholesterol Randomized Trial: What the Evidence Says

Quick Answer

Beta-sitosterol Cholesterol Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• An improvement in the lipid profile, particularly a reduction in low-density lipoprotein cholesterol (LDL-C), is desirable owing to the causal relationship between increased LDL-C and the risk of ASCVD. [Johnen Jana (2026); evidence level 2]
• This effect has been attributed to the increased viscosity of the chyme, formation of a gel on the intestinal mucosal surface, and binding of bile acids, which consequently lowers the re-/absorption of cholesterol and bile acids. [Johnen Jana (2026); evidence level 2]
• Commiphora wightii Phytosterols (PSs) are naturally found plant-based steroidal compounds, which constitute the most significant percentage of unsaponifiable lipid content in plants. [Shahbaz Muhammad (2026); evidence level 2]
• Over 250 phytosterols were found in plant life, with the most common types of phytosterols being 2-sitosterol, campesterol, and stigmasterol. [Shahbaz Muhammad (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For beta-sitosterol cholesterol randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Johnen Jana (2026). Effects of regular consumption of a β-glucan-rich oyster mushroom powder on cholesterol metabolism in adults with moderately elevated LDL-cholesterol concentrations: a double-blind randomized controlled trial. DOI: 10.1186/s12986-026-01122-3. PMCID: PMC13147704. PMID: 42071226. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13147704/
• Shahbaz Muhammad (2026). Anticancer Molecular Mechanisms of Phytosterols: An Updated Review on Clinical Trials. DOI: 10.1002/fsn3.71505. PMCID: PMC12868933. PMID: 41648640. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12868933/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.